MIM
AGRX

MetLife Investment Management’s Agile Therapeutics AGRX Stock Holding History

MetLife Investment Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17
Closed -$102K – 2325
2020
Q3 		$102K Sell
17
-1
-6% -$5.73K ﹤0.01% 2199
2020
Q2 		$99.1K Buy
+18
New +$93.5K ﹤0.01% 2258

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MetLife Investment Management's AGRX Position: Q4 2020 in Review

MetLife Investment Management sold out of Agile Therapeutics (AGRX) in Q4 2020, closing a stake of 17 shares — an estimated $102K sold.

MetLife Investment Management first reported a position in AGRX in Q2 2020 and held it in 2 quarters. The position peaked at $102K in Q3 2020. 76 funds tracked by Wall St. Rank hold AGRX as of Q4 2020.

  • MetLife Investment Management reported no remaining Agile Therapeutics position as of Q4 2020 after selling out during the quarter.
  • MetLife Investment Management sold 17 Agile Therapeutics shares in Q4 2020, an estimated $102K.
  • MetLife Investment Management first reported a position in Agile Therapeutics in Q2 2020 and held it in 2 quarters.
  • MetLife Investment Management's Agile Therapeutics position peaked at $102K in Q3 2020.
  • 76 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2020.

Based on MetLife Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.